GSK (GSK) will discontinue development of camlipixant for refractory chronic cough after the drug produced mixed results in the phase 3 CALM-1 and CALM-2 trials, the company said Friday.

In the phase 3 program, camlipixant 50 mg twice daily significantly reduced 24-hour cough frequency versus placebo in CALM-1 but failed to reach statistical significance in CALM-2, while the 25 mg dose failed to meet the primary endpoint in both trials.

GSK said limited efficacy prompted its decision to discontinue camlipixant's development in refractory chronic cough, while the phase 2b BALANCE trial in irritable bowel syndrome will continue.

GSK shares were down over 3% in premarket activity Friday.